VEGFR-2-IN-51 (compound 19) is an orally active dual-target inhibitor of VEGFR-2 ( IC 50 =15.33 μM) and tubulin ( IC 50 =0.76 μM) with anti-tumor activity. VEGFR-2-IN-51 induces tumor cell apoptosis by reducing mitochondrial membrane potential and increasing reactive oxygen species ( ROS ) levels. VEGFR-2-IN-51 exerts anti-angiogenic effects by blocking the VEGFR-2/PI3K/AKT signaling pathway. In addition, VEGFR-2-IN-51 has significant anti-proliferative activity against the gastric cancer cell line MGC-803 ( IC 50 =0.005 μM).